SCHEMBL5029544

SCHEMBL5029544

O=C(O)N[C@@H]1CC[C@H](N(Cc2ccccc2)Cc2ccccc2)[C@H](CO)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.39
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
EPHX2 P34913 1/20 0.37
MFN2 O95140 1/20 0.36
MAOA P21397 1/20 0.36
ALDH1A1 P00352 4/20 0.35
GAA P10253 2/20 0.35
TSHR P16473 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
LMNA P02545 1/20 0.35
EPHX1 P07099 1/20 0.35
HPGD P15428 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
RAB9A P51151 3/20 0.34
NPC1 O15118 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CTSD P07339 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5029551 1.00 PTGES (0.39) PTGESKMT2AMEN1EPHX2MFN2
SCHEMBL5033614 0.85 PTGES (0.38) PTGESKMT2AMEN1EPHX2MFN2
SCHEMBL5033608 0.85 PTGES (0.38) PTGESKMT2AMEN1EPHX2MFN2
SCHEMBL17802165 0.76 YTHDC1 (0.48) PTGESKMT2AMEN1EPHX2ALDH1A1
SCHEMBL17802164 0.76 YTHDC1 (0.48) PTGESKMT2AMEN1EPHX2ALDH1A1
SCHEMBL3738767 0.72 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1GAATSHR
SCHEMBL5227953 0.72 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1GAATSHR
SCHEMBL3738774 0.72 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1GAATSHR
SCHEMBL19715190 0.71 MFN2 (0.42) KMT2AEPHX2MFN2ALDH1A1GAA
SCHEMBL17007365 0.71 SLC18A3 (0.42) PTGESKMT2AMEN1EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 PTGES 669/4885KMT2A 4093/4885MEN1 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.